PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-55418 | Pharmaceuticals and Healthcare
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Paroxysmal Nocturnal Hemoglobinuria Treatment Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET
7.1 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATMENT MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Achillion Pharmaceuticals Inc
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Akari Therapeutics Plc
16.3 Alexion Pharmaceuticals Inc
16.4 Alnylam Pharmaceuticals Inc
16.5 Amgen Inc
16.6 Apellis Pharmaceuticals Inc
16.7 F. Hoffmann-La Roche Ltd
16.8 ISU ABXIS Co Ltd
16.9 Novartis AG
16.10 NovelMed Therapeutics Inc
16.11 Omeros Corp
16.12 Ra Pharmaceuticals Inc
16.13 Regeneron Pharmaceuticals Inc
16.14 Regenesance BV
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeACH-4471
ALN-CC5
ALXN-1210
AMY-101
APL-2
By Application
Hospital
Clinic
Companies
Achillion Pharmaceuticals Inc
Akari Therapeutics Plc
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
Apellis Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
ISU ABXIS Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Omeros Corp
Ra Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Regenesance BV
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.